Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Indivior Pharmaceuticals (INDV) over the last 3 years, with Q3 2025 value amounting to $106.0 million.

  • Indivior Pharmaceuticals' Other Accumulated Expenses changed N/A to $106.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.0 million, marking a year-over-year change of. This contributed to the annual value of $99.0 million for FY2024, which is 7987.8% down from last year.
  • According to the latest figures from Q3 2025, Indivior Pharmaceuticals' Other Accumulated Expenses is $106.0 million.
  • Indivior Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $492.0 million for Q4 2023, and its period low was $99.0 million during Q4 2024.
  • Its 3-year average for Other Accumulated Expenses is $181.4 million, with a median of $105.0 million in 2025.
  • Over the last 5 years, Indivior Pharmaceuticals' Other Accumulated Expenses had its largest YoY gain of 7987.8% in 2024, and its largest YoY loss of 7987.8% in 2024.
  • Quarter analysis of 3 years shows Indivior Pharmaceuticals' Other Accumulated Expenses stood at $492.0 million in 2023, then tumbled by 79.88% to $99.0 million in 2024, then rose by 7.07% to $106.0 million in 2025.
  • Its Other Accumulated Expenses stands at $106.0 million for Q3 2025, versus $105.0 million for Q2 2025 and $105.0 million for Q1 2025.